# Ash Khanna

> Ash Khanna is a Series B investor at Pivotal bioVenture Partners backing Health Care. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Pivotal bioVenture Partners](https://shizune.co/investors/profile/pivotal-bioventure-partners)
- Location: San Francisco Bay Area, United States
- Total investments: 6
- Last investment: Apr 2023
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/ash-khanna-101854

Ash Khanna is a Series B investor at Pivotal bioVenture Partners in San Francisco Bay Area focused on Health Care and Biotechnology. Ash Khanna is the Partner, Board Member HotSpot Tx, Bolt Bio, Fountain Tx and Evommune of Pivotal BioVenture Partners. He attended the Wharton School.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 50% |
| Biotechnology | 3 | 50% |
| Life Science | 2 | 33% |
| Medical | 1 | 17% |
| Biopharma | 1 | 17% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 33% |
| Series C | 2 | 33% |
| Seed | 1 | 17% |
| Series A | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Evommune | Evommune is taking a tissue-based approach to insights and accelerating the development of transformative medicines for inflammatory diseases. Evommune creates novel strategies to treat inflammatory disorders by developing treatments that address symptoms while also halting disease progression. Evommune's pipeline contains initiatives aimed atcombating highly prevalent inflammatory illnesses. Its mission is to drive real advancements for patients suffering from these diseases, with all of its programs designed to produce best-in-class profiles. | $50M | Series B | Apr 26, 2023 |  |
| HotSpot Therapeutics | HotSpot Therapeutics is a biotech startup that focuses on the development of allosteric therapies targeting regulatory sites on proteins. It develops a therapy platform to discover medicines and provide proper treatment to identify hotspots and locate pathway treatments for cancer, metabolic and rare diseases, leverages a database of hotspotstructures, harnessing the power of data science in its multidisciplinary approach to drug discovery, and helps patients to get treatment against several diseases.HotSpot Therapeutics was founded in 2017 and is headquartered in Boston, Massachusetts. | $100M | Series C | Nov 29, 2021 |  |
| Evommune | Evommune is taking a tissue-based approach to insights and accelerating the development of transformative medicines for inflammatory diseases. Evommune creates novel strategies to treat inflammatory disorders by developing treatments that address symptoms while also halting disease progression. Evommune's pipeline contains initiatives aimed atcombating highly prevalent inflammatory illnesses. Its mission is to drive real advancements for patients suffering from these diseases, with all of its programs designed to produce best-in-class profiles. | $83M | Series A | Sep 09, 2021 |  |
| Evommune | Evommune is taking a tissue-based approach to insights and accelerating the development of transformative medicines for inflammatory diseases. Evommune creates novel strategies to treat inflammatory disorders by developing treatments that address symptoms while also halting disease progression. Evommune's pipeline contains initiatives aimed atcombating highly prevalent inflammatory illnesses. Its mission is to drive real advancements for patients suffering from these diseases, with all of its programs designed to produce best-in-class profiles. | $12.5M | Seed | Nov 18, 2020 |  |
| Bolt Biotherapeutics | Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy. Its platform, Boltbody, is a cancer immunotherapy that consists of immune-stimulating antibody conjugates. | $93.5M | Series C | Jul 01, 2020 |  |
| Bolt Biotherapeutics | Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy. Its platform, Boltbody, is a cancer immunotherapy that consists of immune-stimulating antibody conjugates. | $54M | Series B | Feb 07, 2019 |  |

6 of 6 investments shown.

## Co-investors
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 2 deals together
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 2 deals together
- [LSP BioVentures](https://shizune.co/investors/profile/lsp-bioventures) — VC Fund, 2 deals together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 2 deals together
- [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 2 deals together
- [Amplitude Venture Capital](https://shizune.co/investors/profile/amplitude-venture-capital) — VC Fund, 1 deal together

## About Pivotal bioVenture Partners

VC Fund · San Francisco, United States

Pivotal bioVenture Partners is a $300 million life sciences venture capital fund established in 2017. They invest in privately held North American and European companies focused on innovative therapeutic products and platforms to address major unmet medical needs. They invest at all stages in a company’s evolution, from company creation through midand late stage clinical development. Their team brings diverse experience in venture capital, company building, and drug discovery and development to the table in working with entrepreneurs to advance their businesses.

5 contacts available at Pivotal bioVenture Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Ash Khanna | Partner, Board Member HotSpot Tx, Bolt Bio, Fountain Tx and Evommune | https://shizune.co/investors/profile/ash-khanna |
| Heather Preston | Managing Partner | https://shizune.co/investors/profile/heather-preston |
| Jeni Lee | Partner | https://shizune.co/investors/profile/jeni-lee-ba22 |
| Robert Hopfner | Managing Partner | https://shizune.co/investors/profile/rob-hopfner |
| Vincent Cheung | Managing Partner | https://shizune.co/investors/profile/vincent-cheung-2 |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Ash Khanna invest in?

Ash Khanna invests primarily in Health Care, Biotechnology and Life Science startups, most often at Series B and Series C stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ash Khanna last invest?

The most recent investment recorded for Ash Khanna closed in Apr 2023. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co